Promovax’s general objective is to promote immunizations among migrant populations in Europe, thus contributing to the elimination of vaccine preventable diseases in the region & reducing social inequalities in health. It aims to complement EU policies on reaching hard-to-reach populations by adding to the knowledge of migrants` immunization barriers, developing educational material for both health professionals & migrants and by developing recommendations for policy-makers.
It aims to:
Identify & record the immunization needs of migrants
Evaluate migrants’ access to immunization in the EU countries
Analyze the legislative context regarding migrant immunizations in the partner countries
Identify & exchange best practices on migrants` immunization health promotion
Enhance health care professionals’ knowledge on immunization needs of migrants and raise cultural sensitivity among health care professionals providing for migrants
Improve migrants’ understanding & acceptance of immunizations and facilitate their access to immunizations by identifying a network of relevant sites.


The Joint Action (JA) aims to link and consolidate the objectives of two existing networks dealing with highly infectious bacteria and viruses that emerged from the EU funded project EQADeBa, coordinated by the Robert Koch-Institut (RKI), Germany (EAHC no 2007 204) and the ENP4-Lab project, coordinated by L.Spallanzani National Institute for Infectious Diseases (INMI), Italy (EAHC no 2006 208). The primary objective of the current application is to stabilise both network activities that link 33 partners from 21 European countries highly specialised and advanced laboratories. This will ensure the universal exchange of best diagnostic strategies able to support a European response strategy to outbreaks of highly pathogenic infectious agents plus generating a biodiverse repository of reference materials. The JA will provide a supportive European infrastructure and strategy for external quality assurance exercises (EQAE, bacterial antibiotic susceptibility testing, training, and biosafety and biosecurity review of current practices).


The project aims to further expand the European network of P4 laboratories (high security laboratories), with a focus on biosafety and biosecurity issues and standardisation of diagnostics. Assistance will be offered to EU and international health organisations, to Member States not equipped with P4 laboratories and to new European P4 laboratories.


The general objective of FastVac is to produce a comprehensive set of predictive rules that will enable accelerated development, evaluation, production & release of emergency vaccines. The "blueprints" produced will inform the parallel processes of vaccine development & process design, through to phase 1 clinical testing & support for GMP production. By providing evidence-based rules to aid the production of contingency emergency vaccines, FastVac ultimately aims to have a significant effect on the long term health of the human population, both in the EU & internationally. Specific objectives are to develop: evidence-based rules for rapid vaccine design, production & release; & apply principles for vaccine candidate design based on COPs; & apply principles for the use of COPs in vaccine pre-clinical testing & licensure; production principles that will accelerate vaccine production & release; to consolidate a strategic alliance to respond collectively to vaccine-preventable public health emergencies & to build a strategic framework for uptake of novel concepts for vaccine licensure.


The focus of the conference will be on the discrepancy between the antibiotic
resistance threat and the lack of new drugs foreseen in the pharmaceutical sector. The aim is to explore ways
of creating incentives for the development of new drugs. Such incentives could be changes in the regulatory
mechanisms, innovative financial instruments or other innovative mechanism.
